Cancer cell lines are often used in laboratory experiments as models of tumors, although they can have substantially different genetic and epigenetic profiles compared to tumors. We have developed a general computational method -TumorComparer -to systematically quantify similarities and differences between tumor material when detailed genetic and molecular profiles are available. The comparisons can be flexibly tailored to a particular biological question by placing a higher weight on functional alterations of interest ('weighted similarity'). In a first pan-cancer application, we have compared 260 cell lines from the Cancer Cell Line Encyclopaedia (CCLE) and 1914 tumors of six different cancer types from The Cancer Genome Atlas (TCGA), using weights to emphasize genomic alterations that frequently recur in tumors. We report the potential suitability of particular cell lines as tumor models and identify apparently unsuitable outlier cell lines, some of which are in wide use, for each of the six cancer types. In future, this weighted similarity method may be generalized for use in a clinical setting to compare patient profiles consisting of genomic patterns combined with clinical attributes, such as diagnosis, treatment and response to therapy.
Introduction
Immortalized cancer cell lines, derived from tumors and grown and maintained in vitro, are the most commonly used experimental models in cancer research. Cell lines preserve many properties of tumors, and have been of immense value in advancing the understanding of cancer biology and developing novel therapies over the past decades [1] [2] [3] . However, there are important differences, both in general and in particular tumor types, between the genetic alteration profiles of cell lines and tumors, which are the subject of this study.
While cell lines retain many features of tumors, they also acquire additional changes in the process of immortalization, and during growth and maintenance in culture. Several studies have reported differences between cell lines and tumors with respect to gene expression 4, 5 , methylation [6] [7] [8] , and copy number alterations 9, 10 . In general, cell lines tend to have more genomic alterations than primary tumors, which can be explained by a bias towards using cell lines derived from metastatic tumors 1 , and in-vitro selection of subpopulations of cell lines during long periods of growth and maintenance in the laboratory 1 . Furthermore, the apparent overall difference in mutation burden between cell lines and tumors may be affected by the presence of germline mutations in cell lines, which are explicitly removed from tumor data as matched normal samples are usually available for tumors, but which are incompletely removed from cell line data even with the customary filtering of known common germline variants. In addition, as there is a systematic bias in the source of most immortalized cell lines, cell lines typically do not represent all subtypes of cancers in a particular tissue of origin. In particular, tumor subtypes with the least amount of genetic alterations tend to be under-represented [11] [12] [13] . Given these differences, selecting the most suitable cell line(s) for a specific laboratory investigation becomes a technical challenge of practical interest. In general, cell lines with profiles similar to tumor samples are more suitable than outliers. However, when a set of particular features, such as mutations in particular oncogenes, are required for cell lines to "phenocopy" aspects of tumors, focus on these features would provide more useful assessment of similarity 14 .
Thus, beyond overall genetic similarity, the choice of an appropriate cell line for a specific scientific project crucially depends on the goal and context of the study and comparison algorithms should take the investigator's interest into account. For example, one may want to choose a cell line that is most similar to a set of tumors in terms of alterations in signalling pathways, such as protein phosphorylation cascades; or, in terms of mutations in particular pathways; or, in terms of the overall level of alterations in known oncogenic pathways.
We therefore aimed to develop a general method for adapting the criteria for the choice of cell line most similar to a particular tumor type to the biological question at hand. A simple yet powerful approach is to incorporate feature weights into the measure of similarity of molecular profiles. For example, alterations in genes involved in a certain type of signalling may get a higher weight, others a lower weight. A very simple choice of weights is 1.0 (chosen) and 0.0 (ignored), but in general weights are real numbers 0.0≤w≤1.0. Here, we aimed to derive weights that emphasize potentially oncogenic genomic alterations, while de-emphasizing alterations that are likely to be "passengers" in tumors. We derived such weights (called RA1, for TumorComparer weights based on Recurrent Alterations 1) from TCGA tumor profiles, and then computed the weighted similarity between tumors and cell lines using these weights. We applied the method with RA1 weights to compare tumors of 6 different cancer types from The Cancer Genome Atlas (TCGA) 15 to cell lines from the Cancer Cell Line Encyclopedia (CCLE) 16 , and identified good, moderate and poor matches as well as outlier cell lines to guide cell line selection for laboratory experiments focussed on oncogenic processes.
Results
We developed an approach to comparing tumors and cell lines using multiple data types, using weights to emphasize events relevant to the biological question at hand, e.g. the more frequent and/or known oncogenic events ( Figure 1 ). We then applied our method to compare cell lines and tumors for six different cancer types, using genomic data from 260 CCLE cell lines and 1914 TCGA tumor samples ( Table 1) and weights emphasizing recurrent alterations in tumors. By investigating the nearest neighbours of the cell lines and tumors, we identified the best matching cell lines for the tumors of various types, as well as poor matches and outlier cell lines. 
combined into one composite matrix containing all features to be compared. (b) To compare cell lines and tumors, we used mutations (mutated -green, wild type -white) and copy number alterations (gains -light and dark red, losses -light and dark blue, diploid -white), and chose weights based on recurrence of cancer-type specific and/or pan-cancer events, as a proxy for likely functional events. Table 1 . Tumor and cell line datasets. The 1914 tumors from The Cancer Genome Atlas (TCGA) and 260 cell lines from the Cell Line Encyclopedia (CCLE) used here represent 6 cancer types/subtypes.
Tumors vary more in the extent of alterations by cancer type than do cell lines
We compared mutations and copy number alterations (CNAs) in cell lines from the Cancer Cell Line Encyclopedia (CCLE) and tumors from The Cancer Genome Atlas (TCGA) for six different cancer types (lung adenocarcinoma -LUAD, lung squamous cell carcinoma -LUSC, high grade serous ovarian carcinoma -OV, breast carcinoma -BRCA, colorectal adenocarcinoma -COADREAD, and glioblastoma -GBM). We used cell lines of the corresponding types/subtypes, with two exceptions -all ovarian cell lines were used (since the type annotation is not always unambiguous, and is debatable in some cases, as we recently reported 17 ) , and all CCLE cell lines annotated as "large intestine"
were used as colorectal cell lines.
CCLE provides mutation data for 1651 genes, and we restricted the current analysis to using CNA data for the same subset of genes. CNA data was available for 1529 of these 1651 genes, giving us 3180 alterations or features altogether. Mutations were represented in binary form (1 = 'gene is mutated', 0-'gene is not mutated'), irrespective of location and number of mutations. For copy number changes we used a 5-valued (-2,-1,0,1,2) GISTIC 18 representation.
While our main focus is on detailed comparison of individual tumor profiles with those of potentially useful cell line models, some general trends emerge from the systematic comparison across many cell lines and tumors in a number of different cancer types. First, we confirm the previous observation 6, 9, 13, 17 that cell lines tend to have a larger number of genes affected by somatic mutations or copy number alterations than do tumors ( Figure 2 The second general observation relates to the extent of genetic variation in tumors and cell lines derived from different tissues. We confirm the observation that mutation counts, as well as copy number alterations, are substantially higher for some tumor types than others ( Figure 2 ) 19, 20 . In contrast, cell lines vary less between different tumor types of origin ( Figure 2 ). This observation may be related to mechanisms of immortalization, in-vitro growth or adaptation via passaging.
Figure 2. Tumors vary more in the extent of mutations and copy number alterations by cancer type than do cell lines.
Comparison of the extent of mutation (top) and copy number alteration (CNA, bottom) across six cancer types for cell lines and tumors. While tumors vary remarkably in mutation counts (top left; e.g., the median number of mutations in lung squamous cell carcinoma is nearly six times greater than in breast cancer and five times greater than in high grade serous ovarian carcinoma), the corresponding variation is less than twofold in cell lines (top right). The trend for copy number alterations (bottom) is similar, albeit less pronounced. This difference between tumors and cell lines may be due to alterations acquired by cell lines during immortalization, in-vitro growth and/or adaptation via passaging.
The trend for copy number alterations (bottom) is similar, albeit less pronounced. This difference between tumors and cell lines may be due to alterations acquired by cell lines during immortalization, in-vitro growth and adaptation via passaging. 
All cancer types have a few good tumor matches, and most have some outlier cell lines
To ensure that known and likely oncogenic genomic alterations are emphasized in the comparisons, while differences in likely insignificant or "passenger" alterations are de-emphasized, we aimed to select weights that reflect oncogenic events in tumors. To this end, we utilized the results of the MUTSIG 19, 21 and GISTIC 18 programs for TCGA mutation and CNA data, respectively, and gave higher weights to genes that were identified by MUTSIG as being significantly recurrently mutated, reported by GISTIC as being in a significant CNA peak, and intermediate weights to other genes known to be important in cancer (based on the TCGA pan-cancer analyses of mutation 22 and CNA data 20 ). All other genes had a lower, default weight (see Methods for details).
We assessed the suitability of each cell line as a tumor model using its weighted similarity to the tumors (weight set RA1), calculated as the weighted asymmetric matching score, ignoring zero-zero matches (see Methods for details). Since tumors are themselves a heterogeneous group, often consisting of multiple subtypes, we looked at the mean similarity to k nearest tumors (MSK), instead of mean similarity to the entire tumor cohort. Results are shown for k=10% of tumors in the respective dataset; results were not significantly different for other values of k, e.g. 20%, 30% etc.). We also compared the MSK values of tumors, which estimate tumor-tumor similarity, to the MSK value of each cell line to ascertain whether a given cell line is a good genomic match, a moderately good match, a poor match or an outlier ( Table 2) .
For approximate visual assessment of the proximity of tumors and cell lines, we project them into two dimensions ( Figure 3 ) using multidimensional scaling (MDS) with all-against-all distances between samples as input. Intuitively, cell lines that are close to several tumors on the MDS plots are good genomic matches, those which are far from most tumors are poor matches and outliers, while the remaining cell lines are intermediate matches. Figure 4 shows the MSK scores for all 260 cell lines across the 6 tumor types -the number of cell lines which are good matches (near or exceeding the mean tumor-tumor similarity, near or above the green line) or particularly poor matches (more than two standard deviations away from the mean tumor-tumor similarity levels; below the red line).
Figure 3. All six cancer types have cell lines that are good tumor matches and some outlier cell lines.
The spread of the tumors shows that OV and LUSC are more homogenous than BRCA and LUAD. The position of cell lines in the two-dimensional representation (multi-dimensional scaling) relative to the tumors indicates which cell lines are good matches (near some tumors) and which are poor matches or outliers (far from most/all tumors). Similarities between tumors (small blue dots) from TCGA tumor (sub)types and corresponding cell lines (larger dots, orange to blue, from outliers to good matches) from CCLE were computed using mutation and copy number alteration data with weights reflecting cancer-specific significant genomic alterations (RA1). In the interest of clarity, only the outlier cell lines are labelled (further details in Methods and Supplement Table 1 ). . Most cell lines are moderately good matches to tumors, but some cell lines are clear outliers. Cell line MSK scores (mean similarity to k nearest tumors), with tumor MSK scores in the foreground for six cancer types (k = 10% of tumor dataset, green line: mean tumor MSK score, red line: mean (tumor MSK scores) -2*sd(tumor MSK scores), the threshold for outliers). The MSK scores show that there is a spectrum of good and moderately good to poor tumor matches and outlier cell lines. HS698T  HCT116  HS675T  SNUC4  SW48  LS513  SNU407  LS180  CL34  SNUC5  HCT15  KM12  SNU1040  RKO  CW2  SNU175  GP2D  HRT18  LOVO  HT115  LS411N  SNUC2A  CCK81  SW620  COLO320  SNU81  HCC56  COLO205  CL11  SW837  SKCO1  HT29  T84  SW1116  MDST8  CL40  OUMS23  LS1034  SW1417  HT55  SW480  NCIH508  SW403  NCIH716  SW948  SNU283  CL14  SNU503  LS123  SNU1197  C2BBE1  RCM1  SW1463 U87MG  8MGBA  KS1  AM38  SF126  TM31  GMS10  KNS60  DBTRG05MG  GI1  A172  T98G  KNS42  NMCG1  GAMG  CCFSTTG1  LN18  H4  CAS1  SW1783  SW1088  42MGBA  SNU466  SNU1105  M059K  YH13  MOGGUVW  SNU738  KALS1  SNU626  HS683  SF295  U138MG  BECKER  LN229  YKG1  SNU201  SNU489  DKMG  GOS3 (Figure 4 ). Similarly, SF295, SNU201 and YH13 lack any GBM-specific recurrent CNAs. to BRCA and LUAD. This is in agreement with the TCGA colorectal study 28 , which reported that colorectal cancers showed great variation in mutation rates, with a subset of tumors demonstrating microsatellite instability (often along with hypermethyation and MLH1 silencing) and carrying a much higher mutational burden than the majority of tumors, and another subset of hyper-mutators with yet higher number of mutations, somatic mismatch-repair and POLE mutations 28 . low extent of copy number alterations, making these cell lines representatives of the hypermutated subtype of colorectal cancer rather than outliers. Since the hypermutated subtype is characterized by an exceptionally high mutational burden rather than specific recurrent alterations, comparisons based on finding shared recurrent events (such as here with weights RA1) are likely to identify hypermutated samples as poor matches to most tumors and/or potential outliers. Ovarian Cancer  TOV21G  53  Hypermutated; flat CNA profile  Ovarian Cancer  SKOV3  2918  Fairly quiet and atypical CNA profile  Ovarian Cancer  RMUGS  0  Atypical CNA profile  Ovarian Cancer  RMGI  1 Fairly quiet and atypical CNA profile; lacks TP 53 mutation and has several mutations and CNAs in cancer genes not typically altered in ovarian cancer Table 2 . 28 outlier cell lines from 6 cancer types. The genomic profiles of these cell lines are badly matched to tumors from this cancer type. These cell lines are very probably not good models for tumors. The cell line HCT116 has been recently reported to be hypermutated 29 . Details of alterations for each cell line are in the supplement (Tables S1-S6).
Colorectal cell lines show a lot of intra--cancer type heterogeneity (as do
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Discussion
While cell lines are valuable models of tumors, there are undeniable differences between the two 2,3,6-9,11-13,17,30-33 . Moreover, even tumors of a given cancer type/subtype may differ substantially from each other in terms of their genomic alterations 34 . Thus, there is a need to refine comparisons of tumors samples, by focussing on the most important properties or alterations -at the same time, excluding all but the known important events means that we might miss potentially important shared alterations. Assigning weights to features of interest like specific genomic alterations, activation of a particular signalling pathway etc. allows us to incorporate the degree of importance of various features into our measure of similarity. Thus, including all or most available data along with judiciously chosen weights is an attractive option for comparing pairs of tumors and/or cell lines.
Here we introduced TumorComparer (TC), a weighted similarity based approach to assessing cell line -tumor similarity, and illustrated its use by comparing CCLE cell lines to TCGA tumors for six different cancer types. We used a set of weights -RA1 -that uses TCGA data to strongly emphasise cancer-type-specific recurrent genomic alterations, followed by pan-cancer recurrent alterations. We identified both good and poor genomic matches as well as outliers among the cell lines of all the cancer types. Several of the outliers and poor tumor matches were cell lines that lacked cancer-specific recurrent alterations reported by TCGA. We also flagged a few potentially mislabelled cell lines. Notably, while we found 13 outlier cell lines among ovarian cancer cell lines including five widely used ones, only 2-5 outliers were found in breast, colorectal, tumors and ovarian cell lines used TP53 mutation status, hypermutant status, and mutation status in seven "non-HGSOC" genes, along with correlation with the mean copy number alteration profile of tumors to score cell lines. The weighted similarity approach introduced here is more general and systematic, and all six cancer types/subtypes were studied using a consistent approach to deriving feature weights, and the same similarity measure. Our methodology can be applied to optimize comparison of cancer samples, be they in-vivo or in-vitro, in a flexible and data-driven manner. For instance, in cases where genomic similarity in terms of shared recurrent alterations might be deemed less important than other characteristics such as expression of specific biomarkers, or biological properties like growth characteristics or response to certain therapies 14 , our approach can be adapted to inform the comparison via the incorporation of features reflecting the characteristics of interest, and weights emphasizing said features. A particularly promising application is patient-patient similarity, which is going to be a critical component in personalized cancer therapy. As we acquire more molecular and clinical data along with treatment outcomes, meaningful measures of similarity to previously treated patients will be an invaluable guide for treatment strategies. By emphasising, via choice of weights, determinants of response and resistance to anti-cancer drugs, our approach can be adapted for use in prognosis, assignment to clinical trials and choice of therapy.
Methods
Data acquisition and preprocessing
TCGA data was obtained from the Broad Institute's GDAC portal websites, and cell line data was obtained from the CCLE website 16 . In order to focus on the mutations most likely to be functional, we excluded mutations in introns, 3' and 5' untranslated regions, flanking and intergenic regions, as well as silent and RNA mutations. Data was pre-processed using the Perl and R programming environments 39 .
GISTIC2 on CCLE CNA data GISTIC2 18 was run using the GenePattern 40 website, using the CCLE segmented data downloaded from the CCLE 16 website and all the default parameters, except the "confidence", which was increased from 0.75 to 0.99. We used the discretized 5-valued (-2,-1,0,1,2) gene-wise data produced by the GISTIC algorithm for copy-number analysis.
Assignment of weights to features
In general, feature weights are to be determined depending on the interest of the investigator and the question(s) asked. Here we chose a particular set of weights focussed on genomics alterations observed as recurrent across many cancer samples. We assigned each of the 3180 genomic features (mutations in 1651 genes, and copy number alterations (CNAs) in 1529 of these genes) a weight between 0 and 1 as follows (default weight = 0.01). As alterations in cancer genes that have no statistically significant recurrence in a particular cancer type may still be of biological interest, we gave all known cancer genes from the TCGA pan-cancer studies a weight of 0.1. Genes in the results from the recurrence analysis programs MUTSIG or GISTIC for specific tumor types have high weights as follows: (i) each gene which had a cancer-specific MUTSIG q-value ≤ 0.1 has a weight of 1; (ii) all genes in GISTIC peaks have a weight according to the number of genes in the peak -all genes in a peak that spans n genes have a weight of 1/n. Thus, all genes with significant recurrence of mutation events according to the MUTSIG method and all genes in singleton peaks in the GISTIC method have the maximum possible weight of 1, other GISTIC peak genes have a weight inversely proportional to the size of their peak, all remaining known cancer genes have a weight of 0.1, and the remaining alterations, assumed to be passengers, have a weight of 0.01.
Weighted asymmetric matching
The vast majority of features are zero in most samples, since only a small fraction of genes are mutated in a typical tumor -so 0-0 matches are the "default" or expected case, and not very informative. We computed the weighted similarity of two samples using weighted asymmetric matching, which measures the similarity between two samples after discarding the 0-0 matches (hence "asymmetric", like the Jaccard Index for binary data).
Samples are represented by feature vectors = ( ! , ! , … , ! ) and = ( ! , ! , … , ! ) and a weight vector for feature weights = ( ! , ! , … , ! ), their weighted similarity is calculated as
that is, 0-0 matches are discarded, and the similarity is calculated as the ratio of the sum of weights of features for which the two samples have the same value, to the sum of weights of all features for which at least one of the samples has a non-zero value. This is similar to the widely used Jaccard Index for binary data, in which zero-zero matches are discarded, and the similarity is calculated as the ratio of the intersection to the union of the subsets of features for which the two samples have non-zero values
Evaluation of cell lines using MSK (mean similarity to k--nearest tumors) scores
Since tumor types and subtypes are often inherently heterogeneous, we evaluated cell lines using their similarity to a subset of k tumors, rather than all the tumors.
Once the weighted similarity scores have been computed, it is straightforward to determine the k most similar tumors for any given cell line or tumor (and k).
Using the mean and standard deviation of the MSK scores of tumors, a cell line was deemed to be a poor match if its MSK score was more than two standard deviations below the mean MSK score for tumors, and an outlier if it was more than three standard deviations below the mean MSK score for tumors.
Non--metric multidimensional scaling
We projected tumors and cell lines into two dimensions for approximate visual assessment of their proximity. Multidimensional scaling (MDS) is a method of dimension reduction which, given an input distance matrix, produces a mapping in a lower-dimensional space that preserves the distances in the original space as faithfully as possible. Classical MDS aims to directly compute the distances in the lower dimension so that they are as close to the original distances as possible (via a minimization of the sum of squares of error terms), and if used with Euclidean distances, is equivalent to PCA (principal component analysis) 41 . Non-metric MDS, on the other hand, only aims to preserve the order between the distances, which allows it to potentially achieve a better lowdimensional mapping on datasets with a high variance in the distance matrix.
Since only a low amount of the variance in our data was explained by the first two principal components, we used the isoMDS function from the R package MASS 41 to perform non-metric MDS. isoMDS uses the output of classical MDS (via the function cmdscale) as its initial configuration in the lower dimensional space, and then iteratively re-computes the distances in the lower dimensional space until convergence 41 . Given weighted similarities between 0 and 1, distances were generated as D i,j = 1 -S i,j where D i,j is the distance between samples i and j, and S i,j is the similarity between them.
